Cooley Advises Underwriters on TetraLogic Initial Public Offering

Palo Alto, Calif. – December 26, 2013 – Cooley LLP announced today that it advised the underwriters on TetraLogic Pharmaceuticals, Corp.'s initial public offering. TetraLogic, a biopharmaceutical company that focuses on the discovery and development of Smac mimetics, now trades on the NASDAQ Global Market under the symbol "TLOG."

Underwriters for the offering include Oppenheimer & Co., Guggenheim Securities, and Needham & Company.

The Cooley corporate securities team advising the underwriters was led by partner Brent Siler and included partner Drew Williamson, special counsel Brian Leaf and associate Robert E. Jones. Critical support for the offering was provided by Natasha Leskovsek (FDA regulatory) and Bill Christiansen (intellectual property).

About Cooley LLP

Cooley's attorneys solve legal issues for entrepreneurs, investors and established companies. Clients partner with Cooley on transformative deals, complex IP and regulatory matters, and bet-the-company litigation, often where innovation meets the law.

Cooley has more than 700 lawyers across eleven offices in the United States and China.

Related Contacts
Brian Leaf Partner, Reston
Brent Siler Partner, Washington, DC
Natasha Leskovsek Partner, Washington, DC
Bill Christiansen Partner, Seattle
Drew Williamson Partner, San Francisco